Spondylitis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-08-05
EMA Authorised: Humira (adalimumab) — AbbVie Deutschland GmbH & Co. KG
EMA authorises Humira (adalimumab) for multiple inflammatory diseases across indications, confirming market authorization.